MICHAEL JAMES OVERMAN to Hepatitis A Virus Cellular Receptor 2
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Hepatitis A Virus Cellular Receptor 2.
Connection Strength
0.203
-
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).
Score: 0.203
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.